Evaluation of Diaphragmatic Function After Interscalene Block With Liposomal Bupivacaine
NCT ID: NCT07263295
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
120 participants
INTERVENTIONAL
2025-12-05
2026-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Diaphragm Movement After an Interscalene Block
NCT03636542
Efficacy and Safety of Liposomal Bupivacaine and Ropivacaine in Upper Limb Surgery
NCT06779643
Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine
NCT06235606
Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain
NCT06165991
A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery
NCT06529432
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental Group: 0.5% Hydrochloride Bupivacaine (10ml) + Liposomal Bupivacaine (10ml) for ISBPB
ISBPB block group receiving combined administration of two drugs
0.5% Hydrochloride Bupivacaine 10ml
0.5% Hydrochloride Bupivacaine 10ml for ISBPB
Liposomal Bupivacaine 10mL
Liposomal Bupivacaine 10mL for ISBPB
0.5% Hydrochloride Bupivacaine (20ml) for ISBPB
ISBPB block control group receiving single administration of a single drug
0.5% Hydrochloride Bupivacaine 20ml
0.5% Hydrochloride Bupivacaine 20ml for ISBPB
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.5% Hydrochloride Bupivacaine 20ml
0.5% Hydrochloride Bupivacaine 20ml for ISBPB
0.5% Hydrochloride Bupivacaine 10ml
0.5% Hydrochloride Bupivacaine 10ml for ISBPB
Liposomal Bupivacaine 10mL
Liposomal Bupivacaine 10mL for ISBPB
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged ≥ 18 years
* American Society of Anesthesiologists (ASA) physical status I-III
Exclusion Criteria
* Nerve injury in the upper limb on the surgical side
* Coagulopathy
* Used opioid medications continuously for more than 3 weeks before surgery
* History of pulmonary disease and a pulse oxygen saturation (SpO₂) \< 95% (measured after 5 minutes of rest at room temperature without oxygen supplementation, using a transcutaneous pulse oximeter)
* Refuse to participate or are deemed unsuitable for this trial by the researchers
Withdrawal Criteria:
* Patients voluntarily withdrew their informed consent
* Surgery was canceled or the anesthesia method was changed due to surgical factors before interscalene brachial plexus block
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Diansan Su
Chair of the Department of Anesthesiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, zhejiang 310000
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZJU_2025C116
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.